No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
5-fluorouracil + mitomycin Sensitive: A2 - Guideline
|
5-fluorouracil + mitomycin Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
imiquimod Sensitive: A2 - Guideline
|
imiquimod Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Penile Cancer
|
No biomarker
|
Penile Cancer
|
TIP Sensitive: A2 - Guideline
|
TIP Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Penile Cancer
|
MSI-H/dMMR
|
Penile Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Penile Cancer
|
TMB-H
|
Penile Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Penile Cancer
|
PD-L1 expression
|
Penile Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H + PD-L1 expression + MSI-L/dMMR
|
Penile Cancer
|
TMB-H + PD-L1 expression + MSI-L/dMMR
|
Penile Cancer
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
TMB-H + PD-L1 expression
|
Penile Cancer
|
TMB-H + PD-L1 expression
|
Penile Cancer
|
toripalimab Sensitive: C4 – Case Studies
|
toripalimab Sensitive: C4 – Case Studies
|
CDKN2A mutation
|
Penile Cancer
|
CDKN2A mutation
|
Penile Cancer
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|